Acadia Pharmaceuticals Inc.

ACAD · Nasdaq · ·

比較

$18.13-1.2%11月12日終値

2026年9月30日までの数値（2026年11月5日提出の10-Qより）

1W: -14.6%
1M: -5.8%
3M

Just reported

Q3 2026 results

From Acadia Pharmaceuticals's results release of 2026年11月4日; its quarterly report has since been filed.

Revenue
Actual
$342.3M
+23% y/y
+11% q/q
Guided
—
No guide given
EPS, GAAP
Actual
$0.31
-26% y/y
+72% q/q
Guided
—
No guide given
Operating income, GAAP
Actual
$71.7M
+101% y/y
+90% q/q
Guided
—
No guide given

Company outlook

Full year 2026

Revenue$1.265B – $1.295B+19% y/y Raised +0.8%

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

Keep exploring

The themes Acadia Pharmaceuticals is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.